RE: Not Good28 Nov 2023 20:12
The Company has made significant progress in establishing its commercial channels, engaging end-users and growing the awareness of our Genedrive MT-RNR1 test in particular. The positive independent confirmation and endorsement from NICE, the UKs most prominent health authority, benefits us in promoting the product not only in the UK, but abroad as well. Following this outcome, our next 7 hospitals are expected to be up and running or implementing in the next few months. We expect NICE's recommendation to contribute positive momentum in our commercial progress at other sites as well. Our commercial footprint is quickly expanding with 7 new distributors contracted in the last 3 months. All of this combined with our participation in a separate NICE Diagnostics Assessment Programme for CYP2C19 makes for very exciting times ahead for the Company and our stakeholders."
β¦.
Hoping to see progress on this on Thursday.